General form of registration statement for all companies including face-amount certificate companies

Consolidated Statements of Changes in Shareholders' Deficit

v3.23.2
Consolidated Statements of Changes in Shareholders' Deficit - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Stock To Be Issued [Member]
Subscription Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Balance, value at Mar. 31, 2021 $ 500 $ 56,075 $ 56,649,491 $ 136,000 $ (53,683,268) $ (87,830) $ 3,070,969
Balance, shares at Mar. 31, 2021 5,000,000 607 560,745,180            
Issuance of common stock upon conversion $ 133 421,353   421,486
Issuance of common stock upon conversion, shares     1,329,246            
Conversion of Series B PS to common stock $ 1,007 (1,007)  
Conversion of Series B PS to common stock, shares   (839) 10,068,000            
Conversion of Series D PS to common stock $ 43 (43)  
Conversion of Series D PS to common stock, shares     428,572            
Exchange of Series D PS to Series E PS (3,258,189)   (3,258,189)
Sale of common shares and warrants for cash, less offering costs and commitment shares $ 3,577 17,273,546   17,277,123
Sale of common shares and warrants for cash, less offering costs and commitment shares, shares     35,772,729            
Exercise of warrants related to the sale of common shares $ 110 10,890   11,000
Exercise of warrants related to the sale of common shares, shares     1,100,000            
Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized 3,439,219   3,439,219
Amortization of beneficial conversion feature related to Series E Preferred Shares (3,349,198)   (3,349,198)
Redemption of Series D Preferred shares (2,534,758)   (2,534,758)
Common shares to be issued for the acquisition of the non-controlling interest subsidiary’s remaining equity (3,087,830) 2,000,000 87,830 (1,000,000)
Common shares to be issued for Patent acquisition 5,000,000   5,000,000
Common stock vested to consultants $ 47 221,424   221,472
Common stock vested to consultants, shares     412,500            
Common stock issued to consultants $ 48 158,285   158,333
Common stock issued to consultants, shares     476,946            
Common stock issued to employees $ 18 82,954 24,600   107,572
Common stock issued to employees, shares     275,000            
Common shares to be issued for Technical Rights Agreement 4,762,376   4,762,376
Revision of dividends payable on Series B Preferred Shares (See Note 2) (182,639)   (182,639)
Conversion of Series E Preferred Shares to common stock $ 822 2,879,179     2,880,001
Conversion of Series E Preferred Shares to common stock, shares     8,228,572            
Dividends payable on Preferred Shares   (392,390)   (392,390)
Series B PS Dividends in kind issued 278,400     278,400
Series B PS Dividends in kind issued, shares   232              
Accretion of Series E Preferred Shares (337,834)   (337,834)
Common shares issued for Technical Rights Agreement $ 1,287 4,761,089 (4,762,376)  
Common shares issued for Technical Rights Agreement, shares     12,871,287            
Common shares issued for acquisition of non-controlling interest and Patent acquisition $ 1,386 6,998,614 (7,000,000)  
Common shares issued for acquisition of non-controlling interest and Patent acquisition, shares     13,861,386            
Reclassification of warrants to liability (2,935,000)   (2,935,000)
Common stock to be issued for legal settlement to NSH shareholders 29,388,000   29,388,000
Common stock issued for legal settlement to NSH shareholders $ 2,889 9,413,060 (9,415,950)  
Common stock issued for legal settlement to NSH shareholders, shares     28,494,706            
Common stock issued for financing expense $ 58 137,982   138,040
Common stock issued for financing expense, shares     580,000            
Net loss         (86,297,748) (86,297,748)
Balance, value at Mar. 31, 2022 $ 500 $ 67,500 96,701,607 20,132,650 (150,036,023) (33,133,765)
Balance, shares at Mar. 31, 2022 5,000,000 674,644,124            
Contingent beneficial conversion feature related to the Series E Preferred Shares, fully amortized 99,000 (99,000)  
Amortization of beneficial conversion feature related to Series E Preferred Shares (113,048)   (113,048)
Common stock vested to consultants $ 18 73,106   73,124
Common stock vested to consultants, shares     125,000            
Conversion of Series E Preferred Shares to common stock $ 1,446 1,666,554 (108,000)   1,560,000
Conversion of Series E Preferred Shares to common stock, shares     14,458,127            
Dividends payable on Preferred Shares (277,868)   (277,868)
Series B PS Dividends in kind issued                
Accretion of Series E Preferred Shares (755,333)   (755,333)
Common stock issued for legal settlement to NSH shareholders $ 6,152 19,439,132 (19,445,284)  
Common stock issued for legal settlement to NSH shareholders, shares     61,558,203            
Net loss         (15,988,020) (15,988,020)
Issuance of common shares under financing agreement $ 5,201 3,070,544   3,075,745
Issuance of common shares under financing agreement, shares     52,018,294            
Increase of 10% in Series E Preferred Shares to one holder based on certain rights (156,000)   (156,000)
Common stock issued in business agreement, to be paid from revenue earned 25 56,225 (56,250)  
Common stock issued in business agreement, to be paid from revenue earned, shares     250,000            
Common stock issued in business agreement $ 25 25,975   $ 26,000
Common stock issued in business agreement ,shares     250,000           100,000
Common stock issued from shares payable $ 10 24,590 (24,600)  
Common stock issued from shares payable, shares     100,000            
Balance, value at Mar. 31, 2023 $ 500 $ 80,377 $ 121,156,733 $ 662,767 $ (56,250) $ (167,533,292) $ (45,689,165)
Balance, shares at Mar. 31, 2023 5,000,000 803,403,748